Structure Thera leaps on early data for diabetes/obesity candidate

US clinical-stage biopharma firm Structure Therapeutics’ (Nasdaq: GPCR) shares leapt almost 66% to $62.06 in pre-market activity, after it delivered better-than-expected efficacy and tolerability for its oral GLP-1 GSBR-1290.

In the 28-day Phase Ib study, GSBR-1290 demonstrated significant weight loss supporting once-daily (QD) dosing and an encouraging safety and tolerability profile.

“These positive Phase Ib results support GSBR-1290 as a promising, differentiated oral GLP-1 receptor agonist with once-daily dosing,” said Raymond Stevens, founder and chief executive of Structure. “GSBR-1290 demonstrated an encouraging safety and tolerability profile with no adverse event-related discontinuations and we are encouraged by the weight loss observed following four weeks of treatment. We look forward to sharing results of GSBR-1290 over a longer 12-week period in the Phase IIa study, and we continue to move forward with all activities in order to begin Phase IIb clinical trials in both type 2 diabetes and obesity as planned in 2024.”